<DOC>
	<DOC>NCT02714790</DOC>
	<brief_summary>Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice. MRD results will be relate to treatment outcome and survival analysis variables (Overall Survival, Disease Free Survival, Cumulative Incidence of Relapse)</brief_summary>
	<brief_title>Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Neoplasm, Residual</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<criteria>Diagnosis of Acute Myeloid Leukemia Age &gt; 18 years Intensive chemotherapy as first line curative treatment Observation period: March 2004 September 2014 Bone marrow WT1 expression and Immunophenotyping by multiparametric flow cytometry performed at baseline Written informed consent Diagnosis of Acute Promyelocytic Leukemia Bone marrow WT1 expression and Immunophenotyping by multiparametric flow cytometry NOT performed at baseline Patient ineligible to intensive chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Minimal Residual Disease</keyword>
	<keyword>Wilms Tumor</keyword>
</DOC>